Perrigo Sold the Problem. The Market Is Paying for the Solution.
A 52% rally, another guidance cut, and a CEO betting that simplification—not the quarter—is what matters.
PRGO · Earnings Call · 2026-11-04
The quarter was bad. The stock disagrees.
Perrigo's third quarter was another messy print: all-in net sales of $989 million, down 5.2%; all-in adjusted EPS of $0.60, down $0.20; core adjusted EPS of $0.61, down $0.06. “Third quarter core adjusted earnings per share was $0.61, down $0.06 from the prior year.” — Eduardo Bezerra, CFO · 2026-11-04 The core sales decline did improve sequentially—from -8.3% in Q1 to -3.1% in Q2 to -1.7% in Q3—and core adjusted operating margin climbed from 12.8% to 13.4% to 14.3%. But management still trimmed the 2026 outlook. “The change to our outlook reflects two primary factors: more measured retailer inventory position heading into the cough and cold season, and continued softness in the European consumer environment.” — Eduardo Bezerra, CFO · 2026-11-04 That is the quarter: modest operating progress, another reduction in the near-term guide, and a lot of explanation.Yet the stock is up 52.4% over the last 90 trading days, sitting within 4.8% of its October 16 high. At a $2.19 billion market cap, the equity still trades at just 0.3x revenue. The market is not celebrating the P&L. It is paying for the infant-formula divestiture and the possibility that Perrigo becomes a simpler, less leveraged consumer self-care company.
Infant formula is finally gone—and that is the real event
For more than a year, infant formula was the fly in the story. Management kept saying the strategic review was ongoing; in February, the CFO said the company was “working with the advisers to assess all available options” — Eduardo Bezerra, Chief Financial Officer (CFO) · 2026-02-26, and in May he said there was “nothing more to share at this stage” — Eduardo Bezerra, CFO · 2026-05-06. Now the sale is announced. “The sale of infant formula is an important step. It simplifies our portfolio and operations, improves our margin profile, reduces expected future CapEx, and allows us to focus our people and resources where we have the greatest right to win.” — Albert Manzone, CEO · 2026-11-04 This is the company-unique catalyst: sale of infant formula. It removes a cash-consuming, low-margin, underabsorbed business. The Q3 all-in EPS included roughly $0.12 of unfavorable impact from planned under absorption in infant formula. It also removes a chunk of future capital spending—management had previously flagged a potential $240 million network investment—and the proceeds are earmarked for debt reduction.That matters because Perrigo is still a leveraged story. Effective net cash is -$2.9 billion, and liabilities are 66.9% of assets. On the prior call, the CFO had already pushed the below-3x leverage target out: “we're now anticipating to achieve that level over the next 2 to 3 years” — Eduardo Bezerra, Chief Financial Officer (CFO) · 2026-02-26. The divestiture does not solve that by itself, but it is the first real step.
The Three-S plan is working—just not fast enough to outrun the old excuses
The operating story is genuinely better at the share level. U.S. store brand OTC volume grew 2% and gained 30 basis points of share; key European brands grew 6.5% in value and gained 80 basis points. E-commerce is now 22% of U.S. volume, up from about 13% in 2022, and management is explicitly leaning into that channel. The share in e-commerce point is not boilerplate: it is a structural mix shift where Perrigo already over-indexes. The company is also bundling its Digestive Health portfolio for GLP-1 consumers, a small but smart attempt to move into faster-growing adjacencies.But the guidance cut is the tell. The fresh top-five keyword is retailer inventory positioning, yet this is not a new phenomenon. On the August call, the CFO had already attributed 1.8 points of the core sales decline to retailer destocking: “out of the around 3% decline in core net sales, right? So 1.8 was related to retailer inventory destocking, most notably in Europe.” — Eduardo Bezerra, CFO or Finance Executive · 2026-08-05 Two quarters later, retailers are still the excuse, now framed as not rebuilding ahead of cough and cold. That is the tension: the Three-S plan is real in market share, but not yet real enough in reported sales to absorb another inventory reset.
The cough-and-cold timing is the swing factor. Management says early incidence trends are better, but retailers are carrying less inventory after two soft seasons. “I cannot tell you is whether that replenishment is going to hit more into Q4 or into Q1 of next year.” — Albert Manzone, CEO · 2026-11-04 If it slips, the newly narrowed guidance has little cushion. This is a company that keeps telling investors the problems are external; the stock has now been asked to believe that one more time.
Earnings quality, leverage, and the 2027 punt
The quarter also had a quality-of-earnings asterisk. The adjusted effective tax rate fell to 3.5%, adding about $0.10 to core EPS, while the full-year guide assumes roughly 14%. The tariff benefit was small but real: “For Q3, the benefit of tariffs was about $4.5 million.” — Eduardo Bezerra, CFO · 2026-11-04 That is benefit of tariffs—a broad theme across recent reporters, but a one-time crutch here. Management implicitly concedes the point when discussing 2027: “I am going to be talking less about 2027, and you will hear more about this in the next quarter.” — Albert Manzone, CEO · 2026-11-04 The prior CEO had been more expansive: “2027 is shaping up as a meaningful growth year.” — Patrick Lockwood-Taylor, Chief Executive Officer (CEO) · 2026-02-26 That optimism has been replaced by a list of watch-outs: tax-rate normalization, vanishing tariff benefits, inflation, and reinvestment.The bull case is that the market is finally valuing Perrigo on the post-divestiture portfolio rather than the current earnings stream. The bear case is that the 52% rally has already priced the easy part—the sale announcement—while the hard parts, oral care, cough-and-cold restocking, and deleveraging, remain unproven. GAAP gross margin is still only 30.7%, down 3.7 percentage points year over year, and the adjusted core gross margin of 37.9% was still down 140 basis points.
That is the right diagnosis. The sale of infant formula is the first tangible proof that management can act on it. But the market has already given Perrigo credit for the cleanup. The next leg requires the simpler company to actually grow—and to stop blaming the retailer for the weather.What has held this company back is not the assets, it is complexity. That is what we are taking out quarter-by-quarter.